| Bioactivity | Sotigalimab, a CD40 agonistic monoclonal antibody, can be used for the research of metastatic pancreatic adenocarcinoma[1]. |
| Name | Sotigalimab |
| CAS | 2305607-45-6 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mark H O'Hara, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021 Jan;22(1) |